ALFACELL PROVIDES UPDATE ON MALIGNANT MESOTHELIOMA TRIAL
Alfacell has provided an update on the status of its international, confirmatory Phase IIIb malignant mesothelioma trial for Onconase (ranpirnase), the company's lead investigational drug candidate.
Nearly 90 percent of the patients required per the study design for full patient accrual are now enrolled. Active patient enrollment is ongoing at leading cancer centers in the U.S., Canada, Germany, Italy, Poland, Australia and New Zealand.
Earlier this year, regulatory changes in several large, non-EU countries delayed the opening of new sites for the study. Now, government approvals have been obtained and sites recently opened in Russia, Romania, Mexico and Brazil, the firm said.